PA8469001A1 - Combinaciones de estatina-inhibidor de mmp. - Google Patents

Combinaciones de estatina-inhibidor de mmp.

Info

Publication number
PA8469001A1
PA8469001A1 PA19998469001A PA8469001A PA8469001A1 PA 8469001 A1 PA8469001 A1 PA 8469001A1 PA 19998469001 A PA19998469001 A PA 19998469001A PA 8469001 A PA8469001 A PA 8469001A PA 8469001 A1 PA8469001 A1 PA 8469001A1
Authority
PA
Panama
Prior art keywords
statin
mmp
inhibitor combinations
inhibitor
combinations
Prior art date
Application number
PA19998469001A
Other languages
English (en)
Spanish (es)
Inventor
Bruce David Roth
Roger Schofield Newton
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PA8469001A1 publication Critical patent/PA8469001A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PA19998469001A 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp. PA8469001A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US7826598P 1998-03-17 1998-03-17

Publications (1)

Publication Number Publication Date
PA8469001A1 true PA8469001A1 (es) 2002-09-17

Family

ID=22142950

Family Applications (1)

Application Number Title Priority Date Filing Date
PA19998469001A PA8469001A1 (es) 1998-03-17 1999-03-16 Combinaciones de estatina-inhibidor de mmp.

Country Status (18)

Country Link
EP (1) EP1063991A1 (enExample)
JP (1) JP2002506818A (enExample)
KR (1) KR20010041916A (enExample)
AR (1) AR018113A1 (enExample)
AU (1) AU1591699A (enExample)
BR (1) BR9815745A (enExample)
CA (1) CA2309588A1 (enExample)
CO (1) CO5070670A1 (enExample)
GT (1) GT199900039A (enExample)
HN (1) HN1999000029A (enExample)
MY (1) MY140504A (enExample)
NZ (1) NZ505994A (enExample)
PA (1) PA8469001A1 (enExample)
PE (1) PE20000348A1 (enExample)
SV (1) SV1999000026A (enExample)
UY (1) UY25436A1 (enExample)
WO (1) WO1999047138A1 (enExample)
ZA (1) ZA992106B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
GB0100761D0 (en) 2001-01-11 2001-02-21 Biocompatibles Ltd Drug delivery from stents
AU2005315608B2 (en) 2004-12-15 2011-03-31 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous endothelin producing system and HMG CoA reductase inhibitors
KR101329112B1 (ko) * 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
WO2010005389A1 (en) * 2008-07-11 2010-01-14 Forskarpatent I Syd Ab Oxidized ldl specific antibody-fusion and conjugated proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1217656C (zh) * 1995-11-02 2005-09-07 沃尼尔·朗伯公司 用于调节脂浓度的方法和药物组合物
EP0901466B1 (en) * 1996-05-17 2001-10-31 Warner-Lambert Company Biphenylsulfonamide matrix metalloproteinase inhibitors
NZ334897A (en) * 1996-12-09 2001-02-23 Warner Lambert Co Medicaments for treating and preventing heart failure and ventricular dilatation
TW536540B (en) * 1997-01-30 2003-06-11 Bristol Myers Squibb Co Endothelin antagonists: N-[[2'-[[(4,5-dimethyl-3-isoxazolyl)amino]sulfonyl]-4-(2-oxazolyl)[1,1'-biphenyl]-2-yl]methyl]-N,3,3-trimethylbutanamide and N-(4,5-dimethyl-3-isoxazolyl)-2'-[(3,3-dimethyl-2-oxo-1-pyrrolidinyl)methyl]-4'-(2-oxazolyl)[1,1'-biphe
GT199800126A (es) * 1997-08-29 2000-01-29 Terapia de combinacion.

Also Published As

Publication number Publication date
CA2309588A1 (en) 1999-09-23
EP1063991A1 (en) 2001-01-03
AR018113A1 (es) 2001-10-31
BR9815745A (pt) 2000-11-14
CO5070670A1 (es) 2001-08-28
JP2002506818A (ja) 2002-03-05
NZ505994A (en) 2003-10-31
PE20000348A1 (es) 2000-05-22
HN1999000029A (es) 1999-09-29
AU1591699A (en) 1999-10-11
WO1999047138A1 (en) 1999-09-23
SV1999000026A (es) 2000-01-18
KR20010041916A (ko) 2001-05-25
GT199900039A (es) 2000-09-06
UY25436A1 (es) 2001-10-25
MY140504A (en) 2009-12-31
ZA992106B (en) 1999-09-30

Similar Documents

Publication Publication Date Title
PA8506101A1 (es) Uso de un compuesto acat para fabricar una composicion farmaceutica
ES2164182T3 (es) Benzociclopentanoxazolidinonas que contienen heteroatomos con actividad antibacteriana.
ES2161548T3 (es) Combinacion de un inhibidor de la aldosa reductasa y un inhibidor de la glucogeno fosforilasa.
ES2176755T3 (es) Derivados anticonvulsivos utiles para el tratamiento de la esclerosis lateral amiotrofica.
PT1328269E (pt) Associacao de um antagonista do receptor cb1 e de sibutramina composicoes farmaceuticas que os contem e sua utilizacao para o tratamento da obesidade
GT200100156A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de colesteril ester.
BR9809819A (pt) Compostos e métodos para a inibição da expressão de vcam-1
ES2148345T3 (es) Composicion farmaceutica con ciclosporina a, un derivado de vitamina e y un emulsionante.
UY25714A1 (es) Método para tratar ateroesclerosis empleando un inhibidor de ap2 y combinación.
SV2004001473A (es) Composiciones farmaceuticas de inhibidores de la proteina de transferencia de esteres de colesterilo ref.pc 23132
ES2182874T3 (es) Procedimiento de tratamiento de las uñas.
ES2184340T3 (es) Combinaciones de inhibidores de la enzima de conversion de la angiotensina e inhibidores de la enzima metaloproteinasa matricial.
PT1032414E (pt) Combinacao de um inibidor da enzima de conversao da angiotensina e de um diuretico para o tratamento de perturbacoes microcirculatorias
GT199800177A (es) Combinacion eficaz para el tratamiento de la impotencia .
AU2003296807A1 (en) Cosmetic composition comprising a metalloproteinase inhibitor and a lipopeptide
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
CU20000140A7 (es) Combinaciones de estatina-carboxialquileter
BR9808923B1 (pt) processos para fazer compostos inibidores de ciclooxigenase-2, e, compostos intermediÁrios para fazer inibidores de ciclooxigenase-2.
HN2003000071A (es) Combinaciones de un ligando alfa-2-delta con un inhibidor selectivo de la ciclooxigenasa-2
PA8469001A1 (es) Combinaciones de estatina-inhibidor de mmp.
ES2132539T3 (es) Composiciones insecticidas sinergicas.
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
SV2004000109A (es) Combinacion de inhibidores de mtp e inhibidores de hmg-coa reductasa y su uso en medicamentos ref.lea 33846-sv
PA7801701A1 (es) Compuestos ariltios
HN1997000088A (es) Biarilacetilenos como inhibidores de la metaloproteasa de matriz